The probability of these traditional Chinese medicines entering the country is high (with list)

Over 400 billion Chinese medicine market, which varieties are most likely to be the first to be included in the scope of national collection? 1, 400 billion market of traditional Chinese medicine, ushered in the recent national harvest, the State Health Insurance Administration released the news, has been on Chinese medicine, biologics (insulin) collection of relevant issues to consult experts, plans to promote procurement reform. According to data provided by
, the size of China's pharmaceutical market reached 1735.9 billion yuan last year, an increase of 3.8% over 2018, of which Chinese traditional medicine accounted for 23.1% and the volume was about 401 billion yuan.
there are more than 1,500 Chinese medicine companies in the 400 billion-year-old Chinese medicine market - data show that the number of Chinese traditional medicine companies continued to grow in 2011-2017, from 1,328 in 2011 to 1,736 in 2017.
2018, the total number of enterprises decreased, down 1.84 percent year-on-year to 1,704, as some manufacturers left the market.
an industry authority who did not want to be named said to Seibrand, many of the development of traditional Chinese medicine enterprises can not be separated from large varieties, some even exclusive varieties, gross margin is relatively high, coupled with the new crown outbreak at the beginning of the year, the use of many traditional Chinese medicine increased significantly, a combination of factors, for Chinese medicine to start collection has become imperative.
2, oral Chinese medicine collection is probably the first line according to the Medical Economicnews news, an expert involved in the above-mentioned meeting said that Chinese traditional medicine, biological products, Chinese herbal medicine, the volume of procurement is approaching.
According to the above-mentioned experts revealed that Jinhua City' second batch of volume procurement selected drug catalog stake and variety screening process has a certain first meaning.
according to the observation of Cypress Blue for a period of time, Jinhua City's second batch of collection, the most noteworthy highlight is the introduction of a large number of traditional Chinese medicine.
in the context of the national organization of drug collection will be included in traditional Chinese medicine, Jinhua City's variety selection for the follow-up which Chinese traditional medicine may be included in the scope of national collection has a certain reference significance. On June 8,
, Jinhua City officially announced the second batch of pharmaceutical products purchased in volume, including antimicrobial drugs (non-original research), antibacterial drugs (original research), traditional Chinese medicine (excluding low-cost drugs), Traditional Chinese medicine (including low-cost drugs) four categories, involving a total of 274 drugs.
only traditional Chinese medicine, Jinhua City on a one-time into 180 common varieties, including Qingkailing particles, ginseng injection, degassing capsules and pediblue anti-inflammatory oral liquid and other large varieties.
according to the announcement, Jinhua City, the second batch of drug belt procurement variety screening process is as follows: According to the 2019 Zhejiang Province pharmaceutical procurement platform data, according to the pharmacological role of drugs divided into several categories, after discussion decided to fight infection and Chinese medicine according to the same general name procurement of the top list of drugs, comprehensive consideration of dosage form, specifications, original research or non-original research, excessive consistency evaluation and other factors, the formation of anti-infection drugs, anti-infection drugs, non-identical drugs.
that is, as far as traditional Chinese medicine is concerned, in the case of consistency evaluation, original and non-original research, dosage form, specifications, medical institutions procurement amount is the main screening conditions.
from the dosage form, in addition to ginseng wheat injection, bone melon extract injection, Conlet injection, vein injection, Shu heenning injection, wake-up quiet injection (artificial musk), wake-up quiet injection (natural musk), injection lamp alcanin, Kangai injection, Danhong injection several injections, the rest are oral injection.
, The founder of Beijing Dingchen Pharmaceutical Management Consulting Center Shi Lichen further said to Seibrand, at this stage, Chinese medicine injections in the safety, effectiveness, clinical data and other aspects of some disputes, first included in the national collection of traditional Chinese medicine will be based on oral preparations.
3, which varieties, what rules June 24, Jinhua City released the second batch of the results of the collection, a total of 93 products have been selected in the enterprise, the winning rate of only 21.7% - of which 54 Western medicine, 39 Chinese medicine, ginseng injection, compound dansan tablets, six-flavored yellow pills, clear-kai linguine particles and other chinese medicine collection success.
must see that compared with the previously announced number of expected collection varieties, the final success rate of collection is not high.
industry to Saber Blue analysis, this leads to a second problem, in addition to the establishment of varieties in addition to considering medical institutions and other terminal product use also to take into account the competitive situation of the enterprise side, only a sufficient number of enterprises, as well as products have enough alternative, participating enterprises will be able to have a larger price reduction in the selection of power.
different from the chemical drugs directly in accordance with the generic name of the same variety of enterprises with competitive qualifications, Beijing Shengshi Kanglai Chinese medicine marketing planning company chairman Shen Yong pointed out that the chinese medicine approval as many as 60,000, at least in the production of at least 20,000 or so, different Chinese medicine has a large number of enterprises, some Chinese medicine, production enterprises, conditions to achieve full competition, some Chinese medicine, production enterprises, even only from the full number of enterprises, even from the full number of competition.
industry insiders pointed out that in this case, may be for traditional Chinese medicine, the division of bidding units is not just to look at the generic name.
Shenyong pointed out to Seibrand that, in general, clinical necessity, small side effects, treatment role is more obvious, can be combined with the use of chemical drugs to play a synergy, make up for the lack of clinical treatment of the chinese medicine is the first to be included in the collection of the probability is greater.
in addition, some traditional Chinese medicine involves the selection of traditional chinese medicine, the brand effect is obvious, the national level also has some specific quality standards, these factors may be considered when selecting varieties.
in addition to the selection of varieties, according to the characteristics of traditional Chinese medicine, how to set rules, how to ensure that enterprises have full participation in the bid in the choice of the will is another key issue, after all, to the national collection stage, such a high rate of enterprise abandonment is difficult to be allowed to appear.
Jinhua City set up the evaluation method is the first stage of the first comprehensive consideration of the clinical use of drugs, price, decline and other factors to develop scoring standards, the amount of 20 points, the price of 25 points, a decrease of 40 points.
the top three products in the overall ranking situ into the next stage of expert review.
then confirmthe the winning enterprise based on the sum of the first stage's comprehensive score and expert voting points, with the highest-scoring production enterprises being selected.
selected if the score is the same, the low price of the enterprise. in addition,
, in order to ensure the safety of supply, Jinhua City requires the manufacturers involved in the quotation are committed to their drugs as substitutes, to ensure that they can be timely replacement of the cancelled drugs.
the popularsound of chinese medicine into the country has been heard, in the case of local collection and flowering everywhere, the selection of reference-meaning target analysis, may give a certain degree of inspiration and reference to judge the follow-up trend of national harvest.
attached: Jinhua City included in the second batch of the volume of procurement of Traditional Chinese medicine attached: Jinhua City, the second batch of volume procurement proposed list of enterprises (serial number 55 for Chinese medicine)